Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.5417 -0.0593 (-9.87%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.5500 +0.0083 (+1.53%) 17:26 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.5254
Day High
0.6270
Open 0.5300
Previous Close 0.6010 0.6010
Volume 1,490,200 1,490,200
Avg Vol 546,245 546,245
Stochastic %K 57.12% 57.12%
Weighted Alpha -93.67 -93.67
5-Day Change -0.0083 (-1.51%) -0.0083 (-1.51%)
52-Week Range 0.4600 - 17.8250 0.4600 - 17.8250
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,547
  • Shares Outstanding, K 53,396
  • Annual Sales, $ 0 K
  • Annual Income, $ -134,850 K
  • EBIT $ -142 M
  • EBITDA $ -146 M
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.60
  • Most Recent Earnings $-0.55 on 03/06/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 183.14% ( -86.97%)
  • Historical Volatility 79.07%
  • IV Percentile 46%
  • IV Rank 30.21%
  • IV High 576.90% on 04/10/25
  • IV Low 12.65% on 10/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 461
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 2,140
  • Open Int (30-Day) 2,558

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.56
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +33.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4600 +17.76%
on 04/10/25
Period Open: 0.7172
0.7398 -26.78%
on 03/26/25
-0.1755 (-24.47%)
since 03/25/25
3-Month
0.4600 +17.76%
on 04/10/25
Period Open: 1.5150
1.5600 -65.28%
on 01/27/25
-0.9733 (-64.24%)
since 01/24/25
52-Week
0.4600 +17.76%
on 04/10/25
Period Open: 16.8700
17.8250 -96.96%
on 05/07/24
-16.3283 (-96.79%)
since 04/25/24

Most Recent Stories

More News
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALXO : 0.5417 (-9.87%)
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALXO : 0.5417 (-9.87%)
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

ALXO : 0.5417 (-9.87%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.5562 (-4.65%)
EXEL : 37.43 (+0.59%)
ONC.TO : 0.77 (-4.94%)
ALXO : 0.5417 (-9.87%)
CRDF : 2.88 (-0.69%)
VSTM : 7.50 (unch)
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALXO : 0.5417 (-9.87%)
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALXO : 0.5417 (-9.87%)
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALXO : 0.5417 (-9.87%)
ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALXO : 0.5417 (-9.87%)
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALXO : 0.5417 (-9.87%)
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALXO : 0.5417 (-9.87%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 0.7056
2nd Resistance Point 0.6663
1st Resistance Point 0.6040
Last Price 0.5417
1st Support Level 0.5024
2nd Support Level 0.4631
3rd Support Level 0.4008

See More

52-Week High 17.8250
Fibonacci 61.8% 11.1916
Fibonacci 50% 9.1425
Fibonacci 38.2% 7.0934
Last Price 0.5417
52-Week Low 0.4600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective